Prevention of cancer through immunization: Prospects and challenges for the 21st century. (Q34708041)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Prevention of cancer through immunization: Prospects and challenges for the 21st century (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Doug R Lowy

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

John T Schiller

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

English

0 references

publication date

1 November 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Immunology

9 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

37 Suppl 1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

S148-55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

Hepatitis B virus-induced oncogenesis.

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

Immunogenicity and tolerability of intradermal administration of an HCV E1-based vaccine candidate in healthy volunteers and patients with resolved or ongoing chronic HCV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

The global health burden of infection-associated cancers in the year 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Bovine papillomavirus and cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Helicobacter pylori and gastric cancer: the causal relationship

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Chapter 2: The burden of HPV-related cancers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Papillomavirus infections and human genital cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

The epidemiology of human papillomavirus infections

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Case-control study of human papillomavirus and oropharyngeal cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

A 2‐Year Prospective Study of Human Papillomavirus Persistence among Women with a Cytological Diagnosis of Atypical Squamous Cells of Undetermined Significance or Low‐Grade Squamous Intraepithelial Lesion

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

HPV-1 L1 protein expressed in cos cells displays conformational epitopes found on intact virions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Hepatitis B virus infection: epidemiology and vaccination

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Vaccines for neonatal viral infections: hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

New hepatitis B vaccine formulated with an improved adjuvant system

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Therapeutic vaccination in chronic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Hepatitis C virus infection--pathobiology and implications for new therapeutic options

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Viral hepatitis and liver cancer: the case of hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Multimeric HCV E2 protein obtained from Pichia pastoris cells induces a strong immune response in mice

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Epstein-Barr virus infection in humans: from harmless to life endangering virus-lymphocyte interactions

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

The use of T-cell directed cellular therapies in Australia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Epidemiology of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

The inflammatory and immune response to Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Helicobacter infection and gastric neoplasia

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Pathogenesis of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Effects of vaccination by a recombinant antigen ureB138 (a segment of the beta-subunit of urease) against Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Progress in vaccine development against Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Challenge model for Helicobacter pylori infection in human volunteers

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200737820

7 January 2021

Identifiers

DOI

10.1002/EJI.200737820

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17972339%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference